DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for X-linked nonsyndromic hearing loss — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleX-linked nonsyndromic hearing loss maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside x-linked nonsyndromic hearing loss in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
TetR(D) — Minocycline has a real, experimentally solved structure in complex with this target (PDB 2XPV, 1.49 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet miydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2XPV · 1.49 Å · ligand Minocycline (MIY). Experimental structure, not a prediction.
What the evidence adds up to
A 2008 case report of one patient with X-linked hypophosphataemic osteomalacia and hearing loss showed a temporary improvement of 20–40 dB after steroid therapy, but hearing deteriorated again within four weeks. After one year of fluctuating levels, stabilisation occurred. The authors concluded that steroid therapy may be of some benefit, but the evidence is limited to a single case with no controlled data. No other drug is mentioned in connection with X-linked hearing loss in these abstracts.
The remaining abstracts discuss sensorineural hearing loss generally, not the X-linked form. A 2023 review of sudden sensorineural hearing loss reports natural recovery rates between 32.0% and 65.0%, with approximately 66.0% of patients achieving complete or partial hearing restoration. Recovery occurs within two weeks in most cases, and over 98.0% of those who recover do so within three months. Age over 40, coexisting dizziness, severity of hearing loss, hypertension, and diabetes are associated with poorer outcomes. Systemic steroids and intratympanic dexamethasone are standard treatments for sudden hearing loss, but the review does not address X-linked nonsyndromic hearing loss.
Two other abstracts review drug delivery systems for the cochlea. One from 2008 identifies cell, polymer, and gene transfer technologies as potential approaches for preserving or regenerating spiral ganglion neurons, but it provides no clinical results. A 2019 article emphasises the need to consider patient burden when designing delivery methods for emerging therapies, but again reports no efficacy data for any specific drug. No abstract describes a completed trial or a drug that improved hearing in X-linked nonsyndromic hearing loss.
What is missing is any clinical trial testing a drug specifically for X-linked nonsyndromic hearing loss, any patient stratification by genetic subtype, and any funding directed at that question. The only drug mentioned in connection with X-linked hearing loss—steroids—produced a transient effect in a single patient. Without a proper trial, no conclusion about efficacy is possible.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Otology & Neurotology · 2002 · 133 citations
Treatment of Sudden Sensorineural Hearing Loss with Systemic Steroids and Valacyclovir
AbstractOBJECTIVE: To determine if the addition of an antiviral medication to systemic steroids improves recovery in the treatment of idiopathic sudden sensorineural hearing loss. STUDY DESIGN: Randomized, double-blind, placebo-controlled prospective multicenter clinical trial. SETTING: The study was administrated from a tertiary care center and clinical research institute; patients were enrolled by otolaryngologists in academic and private practice outpatient settings. PATIENTS: Inclusion criteria included 1) loss of at least 30 dB in 3 contiguous frequencies over <3 days in patients with previous audiometry, 2) marked loss of hearing in patients with prior subjectively normal hearing and no previous audiometry, with contralateral hearing taken as baseline, and 3) patients seen within 10 days of onset of hearing loss. Pretreatment evaluation included audiometry and complete blood cell count, complete blood chemistry, and fluorescent treponemal antibody absorption test. Auditory brainstem-evoked response or magnetic resonance imaging was recommended. INTERVENTION: Patients received prednisone (80 mg/d for 4 d, then tapered over 8 d) with placebo or prednisone with valacyclovir (1 g, 3 times a day for 10 days). MAIN OUTCOME MEASURE: 1) Audiometric assessment at presentation, Week 2, and Week 6; 2) Hearing Screening Inventory questionnaire twice weekly for 6 weeks; and 3) acute Short Form-12 questionnaire at presentation and Week 2. RESULTS: Of 105 subjects enrolled in the study, 84 subjects were evaluable. There were no significant differences between placebo and valacyclovir treatment groups in terms of hearing recovery or symptom recovery on the basis of the Hearing Screening Inventory or Short Form-12 questionnaires. No adverse events were related to the use of valacyclovir. CONCLUSION: Within the paradigm used in the current study, an antiviral medication did not provide more benefit than steroid alone in the treatment of idiopathic sudden sensorineural hearing loss.
AAV-Mediated Delivery of the Caspase Inhibitor XIAP Protects Against Cisplatin Ototoxicity
AbstractHYPOTHESIS: Delivery of the gene encoding X-linked inhibitor of apoptosis (XIAP) using an adeno-associated viral (AAV) vector can protect against cisplatin-mediated ototoxicity. BACKGROUND: Cisplatin is a widely used chemotherapeutic agent with significant ototoxic side effects. One possible mechanism of toxicity is apoptotic death of many cochlear cell types. Acute treatment with inhibitors of caspases- enzymes critical for apoptosis- has been shown to prevent hearing loss in vivo, but is too short-acting for therapeutic use. Gene therapy provides a specific and chronic means of delivering potential therapeutic gents. Introducing an anti-apoptotic gene into the cochlea could provide long-term prophylaxis against the ototoxic effects of cisplatin. METHOD: Two groups of rats were treated with unilateral injection into the round window of AAV harboring a gene encoding either XIAP or green fluorescent protein (GFP). After at least two months of gene expression, auditory-brainstem-response (ABR) threshold shifts and outer-hair-cell (OHC) number were measured in these two groups of animals after 72-hour treatment with cisplatin. RESULTS: Consistent with previous reports, uninjected and AAV.GFP-injected ears displayed profound ABR threshold elevations and OHC loss after cisplatin treatment. Ears that had been injected with AAV encoding XIAP, however, were significantly protected from these effects: cisplatin-induced ABR-threshold shift and hair-cell loss were attenuated by as much as 78% and 45%, respectively, when compared with contralateral (untreated) ears. CONCLUSION: XIAP delivery to the cochlea can protect against the audiometric changes and hair-cell loss associated with cisplatin ototoxicity. The efficacy, specificity, and duration of the protective effects make this a potentially attractive therapeutic paradigm.
Expert Opinion on Drug Delivery · 2008 · 48 citations
Novel drug delivery systems for inner ear protection and regeneration after hearing loss
AbstractBACKGROUND: A cochlear implant, the only current treatment for restoring auditory perception after severe or profound sensorineural hearing loss (SNHL), works by electrically stimulating spiral ganglion neurons (SGNs). However, gradual degeneration of SGNs associated with SNHL can compromise the efficacy of the device. OBJECTIVE: To review novel drug delivery systems for preserving and/or regenerating sensory cells in the cochlea after SNHL. METHODS: The effectiveness of traditional cochlear drug delivery systems is compared to newer techniques such as cell, polymer and gene transfer technologies. Special requirements for local drug delivery to the cochlea are discussed, such as protecting residual hearing and site-specific drug delivery for cell preservation and regeneration. RESULTS/CONCLUSIONS: Drug delivery systems with the potential for immediate clinical translation, as well as those that will contribute to the future of hearing preservation or cochlear cellular regeneration, are identified.
Current Opinion in Otolaryngology & Head & Neck Surgery · 2017 · 20 citations
Evaluation and management of syndromic congenital hearing loss
AbstractPURPOSE OF REVIEW: The purpose of this review is to review the evaluation and management of children with syndromic hearing loss. Specific syndromes and the impact of those syndromes on managing hearing loss will be discussed. RECENT FINDINGS: Improved molecular testing has increased the ability to identify syndromes-associated hearing loss. Accurate diagnosis of syndromic hearing loss can guide discussions regarding prognosis and appropriate management options for the hearing impairment. SUMMARY: A significant portion of childhood hearing loss is associated with a syndrome. Depending on the syndrome, surgical intervention including a bone-anchored hearing aid or cochlear implant may be helpful. In the future, targeted gene therapies may become a viable option for treating syndromic hearing loss.
The Journal of Laryngology & Otology · 2008 · 14 citations · open access
Hearing loss and fluctuating hearing levels in X-linked hypophosphataemic osteomalacia
AbstractBACKGROUND AND OBJECTIVE: X-linked hypophosphataemic osteomalacia is the most common of the genetically determined forms of osteomalacia. The occurrence of hearing loss in X-linked hypophosphataemic osteomalacia has been known since 1984. However, observations on the progression of such hearing loss, and suggestions regarding possible therapy, have not previously been published. METHODS: Case report of a patient with X-linked hypophosphataemic osteomalacia and hearing loss, with three years' audiological follow up, description of empirical therapy and literature review. RESULTS: The patient presented with fluctuating hearing. An audiogram showed mild to severe sensorineural hearing loss mainly in the low and high frequencies. A temporary improvement of 20-40 dB after steroid therapy was observed. Four weeks later, hearing had deteriorated again, mainly in the low frequencies. After one year of fluctuating hearing levels, stabilisation occurred. CONCLUSIONS: In X-linked hypophosphataemic osteomalacia, hearing loss occurs predominantly in the low and high frequencies. The hearing loss type and progression pattern point to an endolymphatic hydrops as the pathogenetic mechanism. Steroid therapy may be of some benefit.
Journal of Korean Medical Association · 2023 · 3 citations · open access
Prognostic factors of sudden sensorineural hearing loss
AbstractBackground: Sudden sensorineural hearing loss (SSNHL) refers to rapid and often unexplained decline in auditory acuity. Reported recovery rates for SSNHL vary across studies; however, these are usually within the range of 40% to 60%. Although numerous studies have investigated factors that affect auditory restoration, prediction of patients’ hearing recovery remains challenging.Current Concepts: Natural recovery rates for SSNHL range between 32.0% and 65.0%, and treatments commonly include systemic steroid therapy and intratympanic dexamethasone injections. Adjunctive treatments, such as antiviral agents, vasodilators, anticoagulants, hyperbaric oxygen therapy, and stellate ganglion block therapy are also utilized. Recovery typically occurs within 2 weeks, and approximately 66.0% of patients have complete or partial hearing restoration. Recovery predominantly occurs early; approximately 78.2% to 90.0% patients recover within 1 month and >98.0% within 3 months. Age is an important factor associated with recovery; patients aged ≥40 years show low recovery rates. Coexisting dizziness is generally associated with unfavorable outcomes. Hearing loss severity and types (based on the frequency-specific pattern of hearing impairment) are associated with poor prognosis. Additionally, systemic conditions like hypertension and diabetes are implicated as etiopathogenetic contributors. In addition to a variety of audiological assessments to evaluate cochlear function, environmental factors, including particulate matter and air pollution affect outcomes.Discussion and Conclusion: During SSNHL treatment, evaluation of factors known to affect recovery is important to determine patients’ hearing restoration potential. Proactive patient counseling is necessary to guide treatment decision-making, particularly for initiation of auditory rehabilitation following incomplete or lack of recovery. Significant variables that affect hearing recovery are useful prognostic indicators. These studies are expected to provide better understanding of the pathophysiology of SSNHL and offer an evidence-based foundation for therapeutic interventions.
Archives of Otolaryngology - Head and Neck Surgery · 1972 · 3 citations
MINOCYCLINE THERAPY
Abstract<i>To the Editor</i>.—The use of the antibiotic minocycline in our practice has revealed a propensity to the development of vertigo in six out of 20 patients so treated. We feel that this possible complication of therapy should be brought to the attention of our colleagues. We had the opportunity to investigate a volunteer who developed vertigo on minocycline. Significant in this patient's past history was a sudden hearing loss in the right ear in November 1969, with the simultaneous onset of vertigo which cleared within a few days. The sudden hearing loss responded to medical therapy with an almost complete return of hearing with the exception of a few islands of hearing loss. The patient was placed on minocycline in November 1971, and, as with the other patients, developed disabling vertigo within 24 hours. The vertigo remitted after the cessation of the use of the drug. Because of this
Frontiers in Cellular Neuroscience · 2019 · 2 citations · open access
Delivering Therapeutics to the Cochlea: The Importance of the Patient’s Perspective
AbstractHearing loss represents a major sensory impairment in humans with a strong impact on quality of life. The current standard of care for chronic sensorineural hearing loss is limited to hearing aids and implantable devices like cochlear implants. Treatments for acute hearing loss consist of systemic or intratympanic corticosteroids. Emerging therapies are being developed to prevent hearing loss or to restore it at the cellular level. Many challenges and questions remain as to the delivery of these therapeutics into the inner ear. Scientists, clinicians, and industry stakeholders should always consider the treatment burden from the patient's perspective when designing new drug delivery approaches. This article highlights key issues to consider.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
